VYNE — Vyne Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $19.77m
- -$0.15m
- $0.50m
- 37
- 29
- 42
- 28
Annual income statement for Vyne Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 21 | 0.931 | 0.477 | 0.424 | 0.501 |
| Cost of Revenue | |||||
| Gross Profit | 19.6 | — | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 274 | 39.8 | 34.8 | 29.7 | 44.1 |
| Operating Profit | -253 | -38.9 | -34.3 | -29.3 | -43.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -256 | -44.7 | -33.9 | -27.9 | -39.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -256 | -44.2 | -33.9 | -27.9 | -39.8 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -256 | -73.3 | -23.2 | -28.5 | -39.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -256 | -73.3 | -23.2 | -28.5 | -39.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -142 | -15.5 | -10.7 | -2.71 | -0.935 |